<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003962</url>
  </required_header>
  <id_info>
    <org_study_id>J9825 CDR0000067162</org_study_id>
    <secondary_id>P01CA015396</secondary_id>
    <secondary_id>JHOC-98040902</secondary_id>
    <secondary_id>JHOC-J9825</secondary_id>
    <secondary_id>NCI-H99-0033</secondary_id>
    <nct_id>NCT00003962</nct_id>
  </id_info>
  <brief_title>Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Dose Finding Study of Toxicity and Immunomodulatory Effects of Interleukin-2 Following Allogeneic Bone Marrow Transplantation in Patients at High Risk for Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.

      PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow
      transplantation in treating patients who have hematologic cancer at risk of relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the toxicity and maximum tolerated dose of interleukin-2 following
      allogeneic T-cell depleted bone marrow transplant in patients with hematologic malignancies
      at high risk of relapse. II. Determine the optimal dose of interleukin-2 in this regimen
      which will result in maximal natural killer cell and lymphokine activated killer cell
      activity in vitro.

      OUTLINE: This is a dose escalation study. Patients receive CD34+ stem cell augmented donor
      bone marrow on day 0 on another protocol. Patients then receive interleukin-2 (IL-2)
      subcutaneously on day 30. Treatment continues for 12 weeks in the absence of dose limiting
      toxicity. Cohorts of 4 patients receive escalating doses of IL-2 until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose prior to that which causes at least
      grade 3 toxicity.

      PROJECTED ACCRUAL: A total of 18-24 patients will be accrued for this study within 12-18
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">June 2000</completion_date>
  <primary_completion_date type="Actual">June 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Any of the following diagnoses eligible: Acute myelogenous
        leukemia beyond first complete remission Acute lymphoblastic leukemia Chemotherapy
        resistant non-Hodgkin's lymphoma Chemotherapy resistant Hodgkin's disease Multiple myeloma
        Primary refractory acute leukemia Secondary leukemia Chronic myelomonocytic leukemia No
        chronic myelogenous leukemia, aplastic anemia, or myelofibrosis HLA identical related donor
        required

        PATIENT CHARACTERISTICS: Age: 0.5 to 65 Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: See Disease Characterisitics Hepatic: Bilirubin less than 2.5
        mg/dL (unless Gilbert's syndrome present) Renal: Creatinine no greater than 2 mg/dL
        Cardiovascular: No active congestive heart failure, arrhythmia, or angina pectoris No
        myocardial infarction within past 12 months Pulmonary: No requirement for oxygen Other:
        Afebrile for greater than 48 hours No active, serious infection (e.g., sepsis,
        mucormycosis, or uncontrolled aspergillosis) No debilitating medical or psychiatric illness
        that would preclude compliance Not pregnant Fertile patients must use effective
        contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplant Chemotherapy:
        See Disease Characteristics Endocrine therapy: No concurrent corticosteroids Radiotherapy:
        Not specified Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul V. O'Donnell, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2004</study_first_posted>
  <last_update_submitted>May 1, 2014</last_update_submitted>
  <last_update_submitted_qc>May 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2014</last_update_posted>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

